After Hours
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Most recently, Yahoo Finance reported about the stock as it publicized that Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC262, a Hypoimmune-modified, CD22-directed Allogeneic CAR T Therapy, for Patients with Relapsed or Refractory B-cell Malignancies.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
Sana Biotechnology Inc is listed on the NASDAQ as a member of the Healthcare sector and is a part of the Biotechnology industry. At the end of the last regular session, the stock closed at $6.36 and fluctuated between $6.83 as its day high and $6.01 as its day low. The current market capitalization of Sana Biotechnology Inc is $1.25B. A total of 2.95 million shares were traded on the day, compared to an average of 2.78M shares.
Insider Activity
Additionally, investors take into account insider trades when predicting how a stock will perform. During the recent three months, SANA has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 6 BUYs and 14 SELLs from insiders. Insiders purchased 24,429 shares during that period but sold 12,526,517.
In the most recent transaction, Hordo Christian sold 75,000 shares of SANA for 4.00 per share on Dec 15. After the transaction, the EVP, Chief Business Officer now owns 867,455 company shares. In a previous transaction on Jun 07, Flagship Ventures Fund V Gener sold 200,000 shares at 6.24 per share. SANA shares that 10% Owner owns now total 1,380,277.
Among the insiders who sold shares, Flagship Ventures Fund V Gener disposed of 203,758 shares on Jun 06 at a per-share price of $6.31. This resulted in the 10% Owner holding 1,403,037 shares of SANA after the transaction. In another insider transaction, Flagship Ventures Fund V Gener sold 82,000 shares at $6.23 per share on May 26. Company shares held by the 10% Owner now total 1,425,334.
Though price targets are rarely accurate, they can exert some influence from time to time and were often accepted as valuable by the market. In terms of 52-week highs and lows, SANA has a high of $9.15 and a low of $2.74.
As of this writing, SANA has an earnings estimate of $Banco Santander, S.A. Sponsored per share for the current quarter. EPS was calculated based on a consensus of Cassava Sciences, Inc. estimates, with a high estimate of $Sandstorm Gold Ltd. per share and a lower estimate of $Sana Biotechnology, Inc.
Balance Sheet Annually/Quarterly
A balance sheet is a report that shows the company’s assets and liabilities. In addition, it shows how much equity investors have invested in the company. Investors can determine the company’s prospects by calculating its financial ratios based on this information. SANA’s latest balance sheet shows that the firm has $551.00M in Cash & Short Term Investments as of fiscal 2021. There were $110.94M in debt and $99.23M in liabilities at the time. Its Book Value Per Share was $1.86, while its Total Shareholder’s Equity was $728.50M.
Analysts Opinion
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for SANA is Buy with a score of 4.00.
